Missouri Osteochondral Preservation System Honored with Sports Medicine Technology Award
Missouri Osteochondral Preservation System Honored
with Sports Medicine Technology Award
Preservation system available exclusively from CONMED through MTF Biologics recognized for providing double the storage-life with increased viable chondrocyte density of osteochondral allografts
Edison, N.J. (July 11, 2018) – MTF Biologics today announced that a research team at the University of Missouri has received a Sports Medicine Technology Award for the Missouri Osteochondral Preservation System (MOPSSM). Presented annually by Orthopedics This Week and RRY Publications, LLC, Sports Medicine Technology Awards recognize exemplary and innovative products to treat sports injuries and the engineering teams and inventors who create them.
MOPSSM was selected for a Sports Medicine Technology Award for its ability to more than double the storage life of allografts used for joint repairs, based on two-year data. Developed by a research team at the University of Missouri and available exclusively with tissue processed by MTF Biologics, MOPSSM allografts have been shown to maintain higher viable chondrocyte density for twice as long as standard of care (SOC) allografts based on clinical research to date. They may also demonstrate a lower revision rate than SOC allografts. These grafts are available through an exclusive partnership with CONMED.
“MOPSSM is a true advance in sports medicine and orthopedics, benefitting both surgeons who perform joint repair procedures and the patients they treat,” said Joe Yaccarino, President and CEO of MTF Biologics. “This award is a testament to the University of Missouri team’s innovative spirit and dedication to advancing care and a great tribute to the tissue donors whose gifts make this technology possible.”
“We are honored that MOPSSM has been recognized by Orthopedics This Week with a Sports Medicine Technology Award,” said James L. Cook, DVM, PhD, co-inventor of MOPS and Director of Mizzou BioJoint® Center. “Early results for this unique technology have been very promising, and we are excited to continue to explore ways that MOPSSM can improve outcomes for those in need of cartilage restoration while honoring donors and their families.”
Sports Medicine Technology Awards were featured at the 2018 American Orthopaedic Society for Sports Medicine Annual Meeting (AOSSM) in San Diego, California, July 5-8, 2018.
About MTF Biologics
MTF Biologics, also known as the Musculoskeletal Transplant Foundation, is a non-profit organization based in Edison, N.J. It is a consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. As the world’s largest tissue bank, MTF Biologics saves and heals lives by honoring donated gifts, serving patients and advancing science. Since its inception in 1987, the organization has received tissue from more than 125,000 donors, distributed more than 8 million grafts for transplantation, and awarded over $55M in academic research grants. Through its IIAM subsidiary, it has placed over 55,000 non-transplantable organs for research. Through its Statline subsidiary, it has managed in excess of 10 million donor referrals. For more information, visit www.mtfbiologics.org.
About CONMED
CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. CONMED has a direct selling presence in 19 countries, and international sales constitute approximately 50% of the Company’s total sales. Headquartered in Utica, New York, the Company employs approximately 3,100 people. For more information, visit www.conmed.com.
Media Contact: Christian Lail, 615-610-0307, christian.lail@dvlseigenthaler.com
MTF Biologics is a registered trademark of the Musculoskeletal Transplant Foundation.